Drug
Peficitinib clinical trials
Also written ASP015K.
- studies test it
- 31
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
- ASP015K
- 30
Studies by the year they started
31 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 0
Astellas Pharma Inc (22) · Astellas Pharma Global Development, Inc. (7) · Astellas Pharma China, Inc. (1) · Janssen Research & Development, LLC (1)
Often tested with
Tested in the same studies.
Tacrolimus (2) · Methotrexate (1) · Metformin (1) · Verapamil (1) · Rosuvastatin (1) · Mycophenolic Acid (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses peficitinib is read from its arms, and is right about nine times in ten.
Testing it · 31
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateCompletedPhase 2Astellas Pharma IncNCT01554696Written as peficitinib
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01565655Written as peficitinib
- A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedPhase 3Astellas Pharma IncNCT02308163Written as Peficitinib
- A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedPhase 3Astellas Pharma IncNCT02305849Written as Peficitinib
- A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedPhase 3Astellas Pharma IncNCT01638013Written as Peficitinib
- A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Astellas Pharma IncNCT01096862Written as peficitinib
- A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01711814Written as peficitinib
- A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis SubjectsCompletedPhase 2Astellas Pharma IncNCT01649999Written as peficitinib
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid ArthritisCompletedPhase 1Astellas Pharma IncNCT01754805Written as peficitinib
- A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedPhase 1Astellas Pharma China, Inc.NCT04143477Written as peficitinib
- Pharmacokinetics Study in Patients With Impaired Hepatic FunctionCompletedPhase 1Astellas Pharma IncNCT02586194Written as ASP015K
- Bioequivalence Evaluation of a New and Current Tablet of ASP015KCompletedPhase 1Astellas Pharma IncNCT02531191Written as peficitinib
- Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly VolunteersCompletedPhase 1Astellas Pharma IncNCT01225224Written as peficitinib
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminCompletedPhase 1Astellas Pharma IncNCT02760342Written as peficitinib
- Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal FunctionCompletedPhase 1Astellas Pharma IncNCT02603497Written as ASP015K
- A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Janssen Research & Development, LLCNCT01959282Written as JNJ-54781532 25 mg once daily
- A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015KCompletedPhase 1Astellas Pharma Global Development, Inc.NCT01686217Written as ASP015K ER
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsCompletedPhase 1Astellas Pharma Global Development, Inc.NCT02141425Written as ASP015K
- A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult SubjectsCompletedPhase 1Astellas Pharma Global Development, Inc.NCT02111317Written as ASP015K
- Drug-Drug Interaction Study Evaluating Effects of ASP015K on RosuvastatinCompletedPhase 1Astellas Pharma Global Development, Inc.NCT01959399Written as ASP015K
See all 31 studies that test peficitinib →
Given in every arm · 1 — peficitinib is usual care beside what is tested
Codes
What other systems call peficitinib · ClinicalTrials.gg INT000465
- MeSH (NLM) C000608065peficitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) HPH1166CKXPEFICITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088288peficitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170291PeficitinibOne source FDA
- DrugBank DB11708One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608065 | peficitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | HPH1166CKX | PEFICITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088288 | peficitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170291 | Peficitinib | One source FDA |
| DrugBank | DB11708 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.